Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04495907
Other study ID # 20-M-0047-00
Secondary ID
Status Completed
Phase
First received
Last updated
Start date August 6, 2020
Est. completion date August 31, 2021

Study information

Verified date March 2022
Source Davita Clinical Research
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The purpose of this study is to collect genomic and clinical data among a cohort of hemodialysis patients and analyze the association between genetic markers and the development and severity of illness in response to SARS-CoV-2.


Description:

COVID-19 is a novel illness caused by the SARS-CoV-2 virus. It was declared as a global pandemic on March 11, 2020 and since that time there have been outbreaks on every continent except for Antarctica. Preliminary understanding of the virus suggests that some fraction of the population does not manifest clinical disease in response to infection, others manifest a relatively benign course of illness, and still others develop a fulminant course that eventuates in the need for intensive care, mechanical ventilation, or even death. The genetic and epigenetic basis for differential susceptibility remains unknown. Patients receiving hemodialysis provide a good opportunity to understand genetic and epigenetic susceptibility to SARS-CoV-2. By virtue of their ongoing requirements for care, such patients cannot shelter at home or maintain social distancing, but must instead report to a clinical care setting on a thrice weekly basis. Moreover, such patients often travel to and from dialysis using shared ride services, which furthers opportunity for exposure. Preliminary estimates suggest that rates of SARS-CoV-2 positivity are 2 to 5-fold higher among hemodialysis patients than in the general public. Furthermore, frequent contact with the health care system among dialysis patients makes tracking clinical course comparatively easy. The purpose of this study is to collect genomic and clinical data among a cohort of hemodialysis patients and analyze the association between genetic markers and the development and severity of illness in response to SARS-CoV-2.


Recruitment information / eligibility

Status Completed
Enrollment 412
Est. completion date August 31, 2021
Est. primary completion date April 9, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: - Is 18 years or older at the time of consent - Ability to provide informed consent. - Is currently receiving hemodialysis treatment for end-stage kidney disease at a DaVita dialysis center. - Enrollment in prior genomics study (Additional criteria for type B only)

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
United States DCR Connecticut Bridgeport Connecticut
United States DCR Bronx Bronx New York
United States DCR Canton Canton Ohio
United States DCR El Paso El Paso Texas
United States DCR Las Vegas Las Vegas Nevada
United States DCR Lewisville Lewisville Texas
United States DCR Milwaukee Milwaukee Wisconsin
United States DCR Twin Cities Minneapolis Minnesota
United States DCR Norfolk Norfolk Virginia
United States DCR San Antonio San Antonio Texas
United States DCR Victorville Victorville California

Sponsors (1)

Lead Sponsor Collaborator
Davita Clinical Research

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary SARS-CoV-2 IgG An average of 6 months
Primary Anti-SARS-CoV-2 IgG An average of 6 months